tiprankstipranks
Trending News
More News >
CStone Pharmaceuticals (HK:2616)
:2616
Hong Kong Market
Advertisement

CStone Pharmaceuticals (2616) Price & Analysis

Compare
2 Followers

2616 Stock Chart & Stats


CStone Pharmaceuticals News

2616 FAQ

What was CStone Pharmaceuticals’s price range in the past 12 months?
CStone Pharmaceuticals lowest stock price was HK$1.18 and its highest was HK$8.00 in the past 12 months.
    What is CStone Pharmaceuticals’s market cap?
    CStone Pharmaceuticals’s market cap is HK$10.41B.
      When is CStone Pharmaceuticals’s upcoming earnings report date?
      CStone Pharmaceuticals’s upcoming earnings report date is Aug 21, 2025 which is in 19 days.
        How were CStone Pharmaceuticals’s earnings last quarter?
        CStone Pharmaceuticals released its earnings results on Mar 27, 2025. The company reported -HK$0.087 earnings per share for the quarter, missing the consensus estimate of -HK$0.033 by -HK$0.055.
          Is CStone Pharmaceuticals overvalued?
          According to Wall Street analysts CStone Pharmaceuticals’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
            Does CStone Pharmaceuticals pay dividends?
            CStone Pharmaceuticals does not currently pay dividends.
            What is CStone Pharmaceuticals’s EPS estimate?
            CStone Pharmaceuticals’s EPS estimate is -0.11.
              How many shares outstanding does CStone Pharmaceuticals have?
              CStone Pharmaceuticals has 1,464,715,100 shares outstanding.
                What happened to CStone Pharmaceuticals’s price movement after its last earnings report?
                CStone Pharmaceuticals reported an EPS of -HK$0.087 in its last earnings report, missing expectations of -HK$0.033. Following the earnings report the stock price went up 2.041%.
                  Which hedge fund is a major shareholder of CStone Pharmaceuticals?
                  Currently, no hedge funds are holding shares in HK:2616

                  CStone Pharmaceuticals Stock Smart Score

                  Company Description

                  CStone Pharmaceuticals

                  CStone Pharmaceuticals (2616) is a biopharmaceutical company focused on the development and commercialization of innovative oncology therapies. The company operates in the biotechnology and pharmaceutical sectors, specializing in the research and development of immune-oncology and precision medicine treatments. With a robust pipeline of drug candidates, CStone aims to address significant unmet medical needs in cancer treatment.

                  CStone Pharmaceuticals (2616) Earnings & Revenues

                  2616 Stock 12 Month Forecast

                  Average Price Target

                  HK$6.25
                  ▼(-13.43%Downside)
                  {"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"HK$0","7":"HK$7","1.75":"HK$1.75","3.5":"HK$3.5","5.25":"HK$5.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$6.25</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":6.25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$6.25</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,1.75,3.5,5.25,7],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2023","6":"Sep<br/>2023","9":"Dec<br/>2023","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.27,4.422307692307692,4.5746153846153845,4.726923076923077,4.879230769230769,5.031538461538461,5.1838461538461535,5.336153846153846,5.4884615384615385,5.64076923076923,5.793076923076923,5.945384615384615,6.0976923076923075,{"y":6.25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.27,4.422307692307692,4.5746153846153845,4.726923076923077,4.879230769230769,5.031538461538461,5.1838461538461535,5.336153846153846,5.4884615384615385,5.64076923076923,5.793076923076923,5.945384615384615,6.0976923076923075,{"y":6.25,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.27,4.422307692307692,4.5746153846153845,4.726923076923077,4.879230769230769,5.031538461538461,5.1838461538461535,5.336153846153846,5.4884615384615385,5.64076923076923,5.793076923076923,5.945384615384615,6.0976923076923075,{"y":6.25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":4.11,"date":1677628800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.55,"date":1680307200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3.21,"date":1682899200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.8,"date":1685577600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.49,"date":1688169600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.5,"date":1690848000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.23,"date":1693526400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.85,"date":1696118400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.12,"date":1698796800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.22,"date":1701388800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.14,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.27,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
                  Similar Stocks
                  Company
                  Price & Change
                  Follow
                  Abbisko Cayman Limited
                  Jiangsu Recbio Technology Co., Ltd. Class H
                  HBM Holdings Ltd.
                  Alphamab Oncology

                  Ownership Overview

                  0.37%99.98%
                  Insiders
                  0.37%
                  Mutual Funds
                  ― Other Institutional Investors
                  99.98% Public Companies and
                  Individual Investors

                  Options Prices

                  Currently, No data available
                  ---
                  Popular Stocks
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis